Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.107 | uM | 7528.091 | 0.9215 | 0.8337 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.533 | uM | 7528.091 | 0.8554 | 0.6945 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 2.67 | uM | 7528.091 | 0.8471 | 0.6769 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 13.3 | uM | 7528.091 | 0.8067 | 0.5923 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 7528.091 | 0.5422 | 0.0444 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7529.09 | 0.9634 | 0.8423 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7529.09 | 0.9826 | 0.9241 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7529.09 | 0.9152 | 0.6453 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7529.09 | 0.8368 | 0.3507 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.107 | uM | 7529.09 | 0.9312 | 0.7093 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.533 | uM | 7529.09 | 0.8991 | 0.5823 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 2.67 | uM | 7529.09 | 0.9108 | 0.6277 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 13.3 | uM | 7529.09 | 0.7179 | -0.0364 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 7529.09 | 0.7290 | -0.0034 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000171 | uM | 9044.091 | 1.0358 | 1.1124 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000853 | uM | 9044.091 | 0.9941 | 0.9817 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00427 | uM | 9044.091 | 1.0046 | 1.0144 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0213 | uM | 9044.091 | 1.0003 | 1.0009 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.107 | uM | 9044.091 | 0.9619 | 0.8828 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.533 | uM | 9044.091 | 0.8779 | 0.6333 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 2.67 | uM | 9044.091 | 0.8969 | 0.6888 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 13.3 | uM | 9044.091 | 0.7965 | 0.4041 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 9044.091 | 0.6511 | 0.0264 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0000853 | uM | 10381.092 | 0.9962 | 0.9946 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000427 | uM | 10381.092 | 0.9807 | 0.9726 | 1.4137 |